NEWARK, Del., Sept. 24, 2020 /PRNewswire/ --Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced that its leading candidate, NR082 (rAAV2-ND4, NFS-01 project), was granted an orphan drug designation (ODD) by the U.S. FDA for the treatment of Leber's Hereditary Optic Neuropathy associated with ND4 mutation.
Leber's Hereditary Optic Neuropathy (LHON) is a maternally inherited mitochondrial disease, characterized by acute or subacute, painless vision loss or even loss simultaneously or sequentially, accompanied by central visual field defect and color vision impairment with poor prognosis. It was first reported by German scholar Leber in 1871. It affects about 1-9:100,000 people worldwide. LHON is one of the blinding diseases. The disease mainly occurs in young- and middle-aged men. Currently, there is no effective treatment for LHON. About 70% - 90% of LHON is caused by ND4 mutation of harboring a point mutation at nucleotide 11778 associated with a G-to-A transition. With the development of NR082, AAV-based gene therapy of LHON becomes possible.
"Due to the lack of effective treatment, the quality of life of LHON patients associated with ND4 mutation is very poor, and a huge unmet medical needs have not been fulfilled," said Dr. Alvin Luk, Chief Executive Officer at Neurophth. "NR082 is the first candidate drug developed by Neurophth. It uses recombinant adeno-associated virus serotype 2 to deliver the genetically modified ND4 gene (rAAV2-ND4). After a single intravitreal injection, the gene is translated and expressed in cells, which effectively supplements the function loss caused by endogenous mutation. Through this gene therapy, the electron transport function of mitochondrial respiratory chain was maintained, and the increase of ATP synthesis restored the normal function of mitochondria, which in turn improved the sensory function of the retinal ganglion cells and improved the visual acuity of LHON patients."
Luk added, "the significance of orphan drug designation is that regulators recognize the unmet medical needs of rare diseases like LHON. The recognition of NR082 will reduce the R&D investment to a certain extent and accelerate the progress of clinical trials and marketing registration. Furthermore, Neurophth is committed to fundamentally solve the causes and change the quality of life of patients through a single treatment of gene therapy."
Professor Bin Li, Founder, Chairman and Chief Scientific Officer at Neurophth, said: "NR082 has been granted as orphan drug by U.S. FDA, which further strengthens our focus on gene therapy for rare ophthalmic diseases, and develops more drugs for treatment of ocular genetic diseases, bringing hope to patients with ocular genetic diseases in the world".
*FDA grants orphan drug designation to drugs and biological products designed to safely and effectively treat, diagnose, or prevent rare diseases or conditions affecting less than 200,000 people in the US. According to the Orphan Drug Act of FDA, Orphan Drug Designation (ODD) provides opportunities for grant funding, fast approval channel, and some incentives, such as waiver of New Drug Application (NDA) fees, tax credits for clinical trial expenses and exemption for prescription drug users' fees as well as the products are entitled to a seven-year of market exclusivity and will not be affected by patents.
About NR082 (rAAV2-ND4; NFS-01 Project)
LHON disease is caused by mutations in mitochondrial DNA 11778, 14484 or 3460. ND4 gene of 11778 G>A mutation is the main pathological factor, which exists in 55-70% of European and American patients and 90% of Chinese patients. NR082 (NFS-01 project) is an innovative candidate drug for ophthalmic AAV-based gene therapy. It uses AAV2 vector to express human ND4 gene in the retinal ganglion cells to repair optic neuropathy caused by 11778 G>A mutation.
As early as 2011, Professor Bin Li's team started the world's first LHON gene therapy investigator-initiated trial (IIT) with this candidate drug. Nine subjects who participated in the clinical trial have been followed up for up to 8 years with no serious adverse reactions, and 5 of them have significant improvement in their vision. This result is the longest follow-up record of gene therapy in the world, which has already been published in the Scientific Report, EBioMedicine and Ophthalmology journals, and has fully proven the long-term safety, effectiveness, and durability of AAV gene therapy in clinical settings.
After the gratifying results of the first study, Professor Li's team conducted a more comprehensive IIT clinical study from 2017 to 2018, with 159 subjects (including 10 subjects from Argentina), which is the largest clinical trial in the entire gene therapy in the world. Among those, 143 of the patients has completed the 12-month follow-up and 56.6% showed a significant BCVA (best-corrected visual acuity improved by at least 0.3 LogMAR) improvement. No serious adverse reaction was found. In May 2020, at the 23rd online annual meeting of the American Society for Gene and Cell Therapy (ASGCT) and the online annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Neurophth presented these two clinical research data on the treatment of LHON with NR082 (NFS-01 project of rAAV2-ND4), demonstrating the international advanced level of this research in the field of gene therapy.
Following the positive results of these two IIT trials, Neurophth is actively preparing the China/U.S. IND (Investigational New Drug) applications, and plans to carry out the registration clinical Phase 1/2/3 registration trial to evaluate the safety, efficacy and durability of NR082.
About Neurophth
As a clinical-stage R & D company, Neurophth is committed to exploring and developing new therapies for global patients with ophthalmic diseases. With the help of the mature AAV ophthalmic gene therapy technology platform and the deep understanding of the ophthalmology field by the founding team for decades, Neurophth has established a rich, robust product pipeline, including more than 10 research projects for various ophthalmic diseases, such as dominant hereditary optic atrophy, optic nerve injury diseases, vascular retinopathy, etc., and gradually expanded from rare to common ophthalmic diseases. Additionally, the company is preparing to build a GMP commercial production platform for gene therapy drugs accordance with the international quality standards, and plans to build an ophthalmic gene therapy transformational excellence center, aiming to become a global leader in gene therapy in ophthalmology to benefit patients all over the world.
Prospect of Gene Therapy in Ophthalmology
Inherited retinal diseases (IRDs) have long been regarded as an ideal disease area for gene therapy, because most of the gene mutations leading to the disease have been identified (more than 200 gene defects are associated with the most common IRDS). The eye is, to some extent, an immune privilege. Clinical trials have shown that gene therapy using adeno-associated virus (AAV) or lentivirus (LV) vectors in the eye does not cause systemic side effects and does not cause significant immune responses. The most common IRDs were Retinitis Pigmentosa (RP), Achromatopsia color blindness (ACHM), Leber Hereditary Optic Neuropathy (LHON), Leber Congenital Amaurosis (LCA), Stargardt disease and X-linked Retinoschisis (XLRS).
To date, only one ophthalmic AAV gene therapy product has been approved in the world, namely the first AAV2 gene therapy voretigene neparvovec-rzyl (LUXTURNA; Spark Therapeutics) approved by FDA in December 2017 to treat IRD caused by RPE65 double allele mutation in adult or pediatric patients. The approval of LUXTURNAhas brought confidence and hope to the global ophthalmic gene therapy field. Public information disclosed that at least 20-30 kinds of gene therapy for ophthalmic diseases are in the research and development stage, and the international representative companies include Applied Genetic Technologies Corporation and Meira GTX, and new companies represented by Neurophth have also begun to enter the international stage of ophthalmic gene therapy.
References
Contact:Dr. Alvin LukAlvin.Luk@neurophth.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/neurophth-therapeutics-treatment-of-lebers-hereditary-optic-neuropathy-gene-therapy-nr082-was-granted-orphan-drug-designation-by-us-fda-301138001.html
SOURCE Neurophth Therapeutics, Inc.
- 001 Guidelines for Veterans Agent Orange and Peripheral ... [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 002 CBD and Neuropathy: Almost Magical Pain Relief Benefits [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 003 Peripheral neuropathy - Wikipedia [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 004 Peripheral neuropathy - Symptoms and causes - Mayo Clinic [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 005 What is Neuropathy? | Neuropathy Support Network [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 006 What Is Peripheral Neuropathy? | Living With Peripheral ... [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 007 Neuropathy, Cancer, Information, Resources | CancerCare [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 008 Neuropathy | Cleveland Clinic [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 009 List of Peripheral Neuropathy Medications (11 Compared ... [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 010 Neuropathy - Lab Tests Online [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 011 10 Symptoms of Neuropathy - Bodily Numbness and Tingling [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 012 Peripheral neuropathy - Diagnosis and treatment - Mayo Clinic [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 013 Neuropathy: Symptoms, Causes, Types, Treatment, Nutrition ... [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 014 Neuropathy Types (Diabetic), Causes, Treatment, & Medication [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 015 Peripheral Neuropathy | Johns Hopkins Medicine Health Library [Last Updated On: October 18th, 2018] [Originally Added On: October 18th, 2018]
- 016 NJ Neuropathy Treatment & Surgery - Discover Your Options! [Last Updated On: October 18th, 2018] [Originally Added On: October 18th, 2018]
- 017 Drugs Causing Peripheral Neuropathy - Medications List [Last Updated On: October 18th, 2018] [Originally Added On: October 18th, 2018]
- 018 What Is Neuropathic Pain? Treatment, Medication, Definition [Last Updated On: November 1st, 2018] [Originally Added On: November 1st, 2018]
- 019 Nerve Remedy Reviews [Last Updated On: November 1st, 2018] [Originally Added On: November 1st, 2018]
- 020 Neuropathy - breastcancer.org [Last Updated On: November 1st, 2018] [Originally Added On: November 1st, 2018]
- 021 Diabetic neuropathy - Wikipedia [Last Updated On: November 1st, 2018] [Originally Added On: November 1st, 2018]
- 022 11 Symptoms and Treatments for Neuropathy | Daily Natural ... [Last Updated On: November 1st, 2018] [Originally Added On: November 1st, 2018]
- 023 Neuropathy | LIVESTRONG [Last Updated On: November 1st, 2018] [Originally Added On: November 1st, 2018]
- 024 What Is Diabetic Neuropathy? | NIDDK [Last Updated On: January 6th, 2019] [Originally Added On: January 6th, 2019]
- 025 Polyneuropathy - Wikipedia [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- 026 Peripheral neuropathy - Illnesses & conditions | NHS inform [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- 027 Peripheral Neuropathy | NIDDK [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- 028 Peripheral Neuropathy | Johns Hopkins Medicine [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- 029 Peripheral Neuropathy Symptoms | Pain In Fingers, Toes, & Feet. [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- 030 The Best Treatment for Peripheral Neuropathy in Feet ... [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- 031 10 Causes of Neuropathy - Facty Health [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- 032 There's a Depressing Difference Between The Sewage of Wealthy Areas And Poorer Ones - ScienceAlert [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 033 Stealth BioTherapeutics Does The Deal With Alexion, And Other Headlines: The Good, Bad And Ugly Of Biopharma - Seeking Alpha [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 034 Peripheral Neuropathy Treatment Market 2025: Topmost manufacturers With Size, Regions, Types, Major Drivers, Profits - TheFinanceTime [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 035 Connecting smartphones to depression | News - Inside Tucson Business [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 036 Global Cardiac Autonomic Neuropathy Treatment Market Top Insights 2020:-Novartis, Pfizer and Roche Holding - Tech News Today [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 037 Quality of Life Declines for Patients With Relapsed or Refractory MM Before Progression Appears - AJMC.com Managed Markets Network [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 038 Does Aspirin Protect Against Nonarteritic Ischemic Optic Neuropathy Development in Men? - Monthly Prescribing Reference [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 039 No Link Between Nutritional Deficiencies, Vincristine-Induced Neuropathy in Pediatric Acute Lymphoblastic Leukemia - Cancer Therapy Advisor [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 040 California Medical Evaluators Grows its Network of Pain Medicine Experts in the San Francisco Bay Area - Business Wire [Last Updated On: October 17th, 2019] [Originally Added On: October 17th, 2019]
- 041 How Caregivers and Patients Can Manage Bodily Responses to Stress - FAP News Today [Last Updated On: October 17th, 2019] [Originally Added On: October 17th, 2019]
- 042 Diabetic Neuropathy Drugs Market 2019-2023 | Evolving Opportunities with Pfizer Inc. and Novartis AG | Technavio - Business Wire [Last Updated On: October 17th, 2019] [Originally Added On: October 17th, 2019]
- 043 Surviving breast cancer what comes next? - Hudson Valley 360 [Last Updated On: October 25th, 2019] [Originally Added On: October 25th, 2019]
- 044 PDF Report : Diabetic Neuropathy Market 2019 || Comprehensive Analysis of the market with Competitive Landscape and Forecasts To 2028 - Tech News... [Last Updated On: October 25th, 2019] [Originally Added On: October 25th, 2019]
- 045 Advanced Nerve & Health Center helps breast cancer survivor reverse her neuropathy - KHOU.com [Last Updated On: October 25th, 2019] [Originally Added On: October 25th, 2019]
- 046 Cardiac Autonomic Neuropathy Treatment Market expected to Witness a Sustainable Growth over 2017 2025 - Health News Office [Last Updated On: October 25th, 2019] [Originally Added On: October 25th, 2019]
- 047 UI-led neuropathy consortium receives grant renewal from National Institute of Health - UI The Daily Iowan [Last Updated On: October 25th, 2019] [Originally Added On: October 25th, 2019]
- 048 Addressing Cardiovascular Risk Factors in People with Diabetes - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [Last Updated On: November 12th, 2019] [Originally Added On: November 12th, 2019]
- 049 Diabetic Peripheral Neuropathy Market - Growth, Future Prospects, and Competitive Analysis 2028 - Market Tribunal [Last Updated On: November 12th, 2019] [Originally Added On: November 12th, 2019]
- 050 Chemotherapy Induced Peripheral Neuropathy Treatment Market to Generate Higher Revenues by Entering into Strategic Collaborations says Fortune... [Last Updated On: November 12th, 2019] [Originally Added On: November 12th, 2019]
- 051 Global Neuropathy Pain Treatment Profiling Industry 2019 Market Share, Regional Analysis, Growth Insights, Leading Companies, End Users and Forecast... [Last Updated On: November 12th, 2019] [Originally Added On: November 12th, 2019]
- 052 Neuropathy Pain Treatment Market Set For Rapid Growth and Trend | Statistics Analysis and Opportunities 2024 - News Description [Last Updated On: November 12th, 2019] [Originally Added On: November 12th, 2019]
- 053 Phase 3 Trial of Investigative FAP Therapy AKCEA-TTR-LRx Launching - FAP News Today [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- 054 Study to search for early signs of peripheral neuropathy in people with diabetes - Griffith News [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- 055 Cardiac Autonomic Neuropathy Treatment Market by Size | Growth | Analysis | Trends and Forecasts to 2017 2025 - chronicles24 [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- 056 Diabetic Neuropathy Market: Technological Growth Map over Time to Understand the Industry Growth Rate - Montana Ledger [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- 057 Potential Link Between Tumor Necrosis Factor- and Peripheral Neuropathy Observed With Bortezomib Treatment in Multiple Myeloma - Oncology Nurse... [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- 058 Pain under left armpit: Causes and what to do - Medical News Today [Last Updated On: November 30th, 2019] [Originally Added On: November 30th, 2019]
- 059 ASH 2019: Brentuximab Vedotin in Combination with Nivolumab in Frontline and R/R Hodgkin Lymphoma - OncoZine [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 060 Medical News Today: Lung cancer complications: Signs, treatment, and outlook - Stock Daily Dish [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 061 Global Neuropathy Pain Treatment Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - World Industry Reports [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 062 Health watch: 5 things to know about chemotherapy - StarNewsOnline.com [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 063 Neuropathy Pain Treatment Market 2019 Share, Growth, Region Wise Analysis of Top Players, Application, Driver, Existing Trends and Forecasts 2026 -... [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 064 Chemotherapy Induced Peripheral Neuropathy Market to Witness a Sluggish Growth Owing to Stringent Government Policies in 2019 - 2029 - Markets Gazette... [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 065 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Industry... [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 066 Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic... [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 067 Looney gives up two aspects of diet to combat neuropathy - NBCSports.com [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 068 What You Need to Know About the FDA - Curetoday.com [Last Updated On: December 30th, 2019] [Originally Added On: December 30th, 2019]
- 069 3 Affordable Herbs & Vitamins that you should try for nerve pain relief - Explosion [Last Updated On: December 30th, 2019] [Originally Added On: December 30th, 2019]
- 070 Diabetic Neuropathy Market Poised to Take Off by 2026 - Market Research Sheets [Last Updated On: December 30th, 2019] [Originally Added On: December 30th, 2019]
- 071 Leber's Hereditary Optic Neuropathy, 2019 - Pipeline Review, H2 - ResearchAndMarkets.com - Business Wire [Last Updated On: January 3rd, 2020] [Originally Added On: January 3rd, 2020]
- 072 Diabetic Neuropathy Market Innovations, And Top Companies Forecast To 2029| Pfizer Inc, Eli Lilly and Company, Actavis Pharma Inc - Neptune Pine [Last Updated On: January 3rd, 2020] [Originally Added On: January 3rd, 2020]
- 073 The health benefits of lemon water | News - WPSD Local 6 [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- 074 NeuroMetrix Reports Q4 and Full Year 2019 Financial Results - BioSpace [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- 075 Fighting the Fire: Battling Rare Neuropathy, San Juan Hills' Efstathiou Coaches with New Perspective - Capistrano Dispatch [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- 076 Peripheral Neuropathy Symptoms, Causes, Treatment & Prognosis [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- 077 A 40-Year-Old Man With Dizziness, Confusion, and Neuropathy - Medscape [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- 078 Neuropathy Signs, Symptoms, and Diagnosis | Everyday Health [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- 079 Peripheral Neuropathy Fact Sheet | National Institute of ... [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- 080 Peripheral Neuropathy: Causes, Symptoms and Treatments [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]